Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard Mega Cap Growth ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard Mega Cap Growth ETF trades at $91.14 (market cap $33.70B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 3.3× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Mega Cap Growth ETF for 45 Days on average.
| GMED | MGK | |
|---|---|---|
Market Cap | $10.25B | $33.70B |
Volume | 1,108,124 | 775,002 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $95.11 |
52-Week Low | $58.33 | $70.70 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MGK, the Vanguard Mega Cap Growth ETF, trades at $94.19, up 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking large-cap U.S. growth stocks like Nvidia and Apple, lacks disclosed fundamental ratios but benefits from a low 0.05% expense ratio and recent positive media coverage highlighting its long-term growth potential and tech concentration.
The outlook for MGK is favorable for growth-oriented investors, driven by its focus on mega-cap tech leaders, though concentration risk and market volatility pose challenges. Analyst sentiment is broadly positive, with the ETF positioned to capitalize on sustained growth trends, but investors should weigh its reliance on top holdings against diversification needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
